FGFR

FGFR

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins.Pathological conditions involve some of these receptors. Achondroplasia can be brought on by a point mutation in FGFR3. Vertebrates have been found to contain five distinct membrane FGFRs, all of which are members of the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). One of the most significant families of paracrine factors that function in the development process is the fibroblast growth factor family. They control which cells differentiate into mesoderm, the production of blood vessels, the growth of limbs, and the growth and differentiation of many different cell types.

FGFR related products

Structure Cat No. Product Name CAS No. Product Description
V3276 ACTB-1003 939805-30-8 ACTB-1003 is an orally available multi-kinase inhibitorwithIC50values of 6, 2 and 4 nM forFGFR1,VEGFR2andTie-2.
V5247 Alofanib (RPT835) 1612888-66-0 Alofanib (known aslso as RPT835) is a novel, potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2) with anticancer and antiangiogenic activity.
V5222 ASP-5878 1453208-66-6 ASP5878 is a novel, potent,selective and orally bioactive inhibitor of FGFR 1, 2, 3, and 4, with IC50values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity.
V2693 BLU-554(BLU-554) 1707289-21-1 BLU-554 is a novel potent, highly-selective, and orally bioavailable inhibitor of FGFR4 (fibroblast growth factor receptor 4) with an IC50 value of 5 nM in cell free assays.
V0617 BLU9931 1538604-68-0 BLU9931 (BLU-9931; BLU 9931) is an irreversible and selective FGFR4 inhibitor with potential anticancer activity.
V37655 BO-264 2408648-20-2 BO-264 is a novel and orally bioactive transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC50 of 188 nM and a Kd of 1.5 nM.
V0618 CH5183284 (FF-284; Debio-1347) 1265229-25-1 CH5183284 (also known as FF284; Debio-1347) is a novel, potent, selective and orally bioavailable FGFR inhibitor with potential antitumor activity.
V69468 CPL304110 1627826-19-0
V3693 Derazantinib (ARQ-087) 1234356-69-4 Derazantinib (formerly known as ARQ 087) is a novel, orally bioavailable, ATP competitive, small molecule, multi-kinase inhibitor with potent in vitro and in vivo activity against FGFR (fibroblast growth factor receptor) addicted cell lines and tumors withIC50s of 4.5, 1.8, and 4.5 nM forFGFR1-3 respectively in biochemical assay, IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3.
V3694 Derazantinib racemate 2309668-44-6 Derazantinib Racemate is the racemic mixture of derazantinib which is formerly known as ARQ 087 and is a novel, orally bioavailable, ATP competitive, small molecule, multi-kinase inhibitor with potent in vitro and in vivo activity against FGFR (fibroblast growth factor receptor) addicted cell lines and tumors withIC50s of 4.5, 1.8, and 4.5 nM forFGFR1-3 respectively in biochemical assay, IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3.
V69485 Efruxifermin 2375240-92-7
V69465 Fazpilodemab (BFKB8488A) 2517935-02-1
V0616 Fexagratinib (AZD-4547; ADSK-091) 1035270-39-3 AZD4547 (AZD-4547; AZD 4547) is a novel and orally bioavailable FGFR (fibroblast growth factor receptor) inhibitor with potential antineoplastic activity.
V69458 FGFR-IN-1 1513860-41-7
V69466 FGFR-IN-11 2658488-68-5
V69464 FGFR-IN-12 943189-02-4
V78857 FGFR-IN-9
V78963 FGFR1 inhibitor 7
V69473 FGFR1 inhibitor-10 2426769-76-6
V69471 FGFR1 inhibitor-2 2410612-08-5
Contact Us